Patents Assigned to Institut National de la Santa et de la Recherche
Medicale
-
Patent number: 10894042Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.Type: GrantFiled: November 10, 2015Date of Patent: January 19, 2021Assignees: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7Inventors: Alain Couvineau, Valérie Gratio, Pascal Nicole, Thierry Voisin
-
Patent number: 10758615Abstract: The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.Type: GrantFiled: January 14, 2016Date of Patent: September 1, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIERInventors: Alain Couvineau, Thierry Voisin, Pascal Nicole, Bruno Robert, Pierre Martineau, Myriam Chentouf
-
Patent number: 10087220Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SEQ ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.Type: GrantFiled: January 15, 2013Date of Patent: October 2, 2018Assignee: INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Michele Aguera, Jean-Christophe Antoine, Marie-Francoise Belin, Jerome Honnorat, Veronique Rogemond
-
Patent number: 10059704Abstract: A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN? groups, together with the carbon atoms to which they are bound, form a monocyclic or bicyclic azacycloalkane group. The pharmaceutically acceptable salts thereof, the hydrates or polymorphic crystalline structures thereof, and to the racemates, diastereoisomers, or enantiomers thereof are also described.Type: GrantFiled: April 20, 2012Date of Patent: August 28, 2018Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Sylvain Routier, Franck Suzenet, Frederic Pin, Sylvie Chalon, Johnny Vercouillie, Denis Guilloteau
-
Patent number: 9365820Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a novel human embryo co-culture system to improve human embryo growth in vitro and, consequently, increase pregnancy rates in infertile women undergoing in vitro fertilization (IVF) treatment. More particularly, the present invention relates to a method of growing an embryo to a blastocyst stage of development comprising the step of coculturing said embryo in the presence of a population of cumulus cells.Type: GrantFiled: November 5, 2014Date of Patent: June 14, 2016Assignees: Institut National de la Santa et de la Recherche Medicale (INSERM), Université Montpellier 1, Centre Hospitalier Universitaire de MontpellierInventors: Samir Hamamah, Said Assou
-
Patent number: 8986936Abstract: The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker.Type: GrantFiled: May 20, 2010Date of Patent: March 24, 2015Assignees: Inserm (Institut National de la Santa et de la Recherche Medicale), Institute Pasteur de Lille, Le Centre Hospitalier Regional Universitaire de Lille, Universite de RouenInventors: Florence Pinet, Paul Mulder, Christophe Bauters, Vincent Richard
-
Publication number: 20130243755Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SED ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.Type: ApplicationFiled: January 15, 2013Publication date: September 19, 2013Applicant: INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)Inventor: Institut National De La Santa Et De La Recherche Medicale (INSERM)
-
Patent number: 8530162Abstract: The present invention pertains to a novel method for quantifying VEGF various isoforms in a biological sample, with a very high selectivity and sensitivity. It also concerns a method for establishing a diagnostic and/or a prognosis concerning a patient potentially suffering from cancer, diabetes, or cardiovascular disease, comprising a step of determining the level of at least one of the VEGF isoforms, in a biological sample from said patient.Type: GrantFiled: June 14, 2005Date of Patent: September 10, 2013Assignees: INSERM (Institut National de la Santa et de la Recherche Medicale), Assistance Publique-Hopitaux de ParisInventors: Fabien Calvo, Samia Mourah, Benyoussef Naimi
-
Publication number: 20130029925Abstract: The present invention relates to the use of a specific family of glycerolipid compounds of formula (I) described in the detailed description or the manufacture of a medicament for the prevention or for the treatment of cancer metastasis.Type: ApplicationFiled: February 17, 2011Publication date: January 31, 2013Applicants: UNIVERSITE DE BRETAGNE OCCIDENTALE (U.B.O.), INSERM ( INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE FRANCOIS-RABELAIS DE TOURSInventors: Christophe Vandier, Philippe Bougnoux, Aurelie Chantome, Bernard Corbel, Alban Girault, Jean-Pierre Haelters, Virginie Joulin, Marie Potier-Cartereau, Gaelle Simon
-
Patent number: 7976843Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.Type: GrantFiled: August 6, 2008Date of Patent: July 12, 2011Assignees: Institut National de la Santa et de la Recherche Medicale (Inserm), Institut Gustave Roussy (IGR)Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, David Alexandre Gross
-
Patent number: 7238693Abstract: The present invention relates to novel compounds, the preparation and use, particularly therapeutic, thereof. More specifically, it relates to compounds derived from aryl carbamates, the preparation and use thereof, particularly in the field of human and animal health. The compounds according to the invention are preferably 5-HT4 serotoninergic receptor ligands and can therefore be used in the therapeutic or prophylactic treatment of any disorder involving a 5-HT4 receptor. The invention also relates to pharmaceutical compositions comprising such compounds, the preparation and use thereof and treatment methods using said compounds.Type: GrantFiled: February 22, 2002Date of Patent: July 3, 2007Assignees: Cerep, Centre National de la Recherche Scientifique, Institut National de la Santa et de la Recherche Medicale (inserm)Inventors: Eric Nicolai, Sophie Curtet, James Sicsic, Frank Lezoualc'h, Rodolphe Fischmeister, Michel Langlois, Magali Maillet, Michèle Launay
-
Patent number: 7101711Abstract: The invention provides compounds comprising at least one phosphoepoxide group of the formula: where R1 is selected from among —CH3 and —CH2—CH3, Cat+ is an organic or inorganic cation, n is an integer between 2 and 20, processes for the production thereof and uses thereof, in particular therapeutic uses and for activating primate T?9?2 lymphocytes.Type: GrantFiled: August 27, 1999Date of Patent: September 5, 2006Assignee: Institut National de la Santa et de la Recherche MedicaleInventors: Christian Belmant, Jean-Jacques Fournie, Marc Bonneville, Marie-Alix Peyrat
-
Patent number: 6521814Abstract: The invention relates to methods for treatment of neurological disease by administering an agent which interacts with a retinoid receptor associated with the neurological disease. The invention is also related to a method of modulating dopamine receptor synthesis by introducing an agent that interacts with a retinoid receptor associated with the dopamine receptor synthesis. The invention is further related to a transgenic animal, e.g., mouse, and mammalian cell line, which is deficient in the normal synthesis of one or more receptors of RAR&agr;, &bgr;, &ggr; and RXR, and cell line thereof.Type: GrantFiled: December 22, 1998Date of Patent: February 18, 2003Assignees: Institut National de la Santa et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Louis Pasteur, Bristol-Myers Squibb CompanyInventors: Pierre Chambon, Emiliana Borrelli, Norbert B. Ghyselinck, Valérie Dupé, Manuel Mark, Daniel Metzger
-
Patent number: 6488639Abstract: The invention concerns an apparatus for treating a biological sample by emitting focused high intensity ultrasounds towards a focal point, characterised in that it comprises means emitting wideband focused ultrasounds. The apparatus enables to adjust the focused ultrasound frequency according to the target attenuation, the thickness of the tissues traversed, the temperature evolution, or the lesion displacement during emission.Type: GrantFiled: January 5, 2001Date of Patent: December 3, 2002Assignees: Technomed Medical Systems, S.A, Institut National de La Santa et de La Recherche MedicaleInventors: Mathieu Ribault, Francois LaCoste, Jean-Yves Chapelon, Emmanuel Blanc
-
Patent number: 6391553Abstract: The invention concerns a method for diagnosing Alzheimer disease, consisting in demonstrating one or several mutations in the genomic DNA region regulating the expression of the apolipoprotein E gene, inducing a modification of the apolipoprotein E gene, with respect to a control population or a modification of the expression relative to the alleles of the apolipoprotein E gene.Type: GrantFiled: March 16, 2000Date of Patent: May 21, 2002Assignees: Institut Pasteur de Lille, Institut National de la Santa et de la Recherche Medicale (Inserm)Inventors: Marie-Christine Chartier-Harlin, Jean-Charles Lambert, Philippe Amouyel
-
Patent number: 6379320Abstract: An ultrasound applicator for heating, via an internal path, an ultrasound absorbent medium, includes an application head having a longitudinal axis and including at least one ultrasonic transducer having a planar emission face and an opposite face, a leakproof membrane which overlays and is spaced from the emission face, and which is transparent to ultrasound, and means for preventing propagation of ultrasound from the opposite face; means for remotely connecting the transducer to an electricity generator; and means for providing ultrasound coupling with the membrane. The planar emission face emits ultrasound waves through the membrane and in a direction that is substantially perpendicular to the emission face, such that the waves emitted are substantially planar and do not diverge in the vicinity of the transducer and the application head.Type: GrantFiled: March 2, 2000Date of Patent: April 30, 2002Assignee: Institut National de la Santa et de la Recherche Medicale I.N.S.E.R.M.Inventors: Cyril Lafon, Jean-Yves Chapelon, Dominique Cathignol, Frederic Prat
-
Patent number: 6225458Abstract: The invention relates to a process for producing DNA corresponding to that of the DNA of the virus of B hepatitis. It comprises cloning in bacteria the latter DNA, previously repaired by means of the corresponding precursor nucleotides in the presence of a polymerase. The invention also relates to vectors containing said cloned DNA in their genomes. The cloned DNA is useful as a probe for detecting the presence of the virus of B hepatitis in biological samples, particularly blood or plasma. Its expression in bacteria provides a hybrid protein containing a protein fragment having vaccinating properties against hepatitis B.Type: GrantFiled: November 23, 1994Date of Patent: May 1, 2001Assignees: Institut Pasteur, Institut National de la Santa et de la Recherche MedicaleInventors: Pierre Tiollais, Alex Fritsch, Christine Pourcel, Patrick Charnay
-
Patent number: 6113902Abstract: An immunogenic composition for treating and/or preventing infectious diseases where the infectious agent has at least one intracellular phase in the host during its multiplication cycle, is disclosed. The immunogenic composition comprises at least one cryptic epitope of a cellular element that is carried along by an intracellular infectious agent as it leaves the cell, and revealed by said infectious agent. A composition for treating and/or preventing HIV infections, antibodies to a peptide of interest, and a diagnostic method, are also disclosed.Type: GrantFiled: February 19, 1997Date of Patent: September 5, 2000Assignee: Institut National de la Santa et de la Recherche Medicale (Inserm)Inventors: Jean-Claude Chermann, Carole Le Contel, Pascale Galea
-
Patent number: 6040142Abstract: The invention relates to methods and compositions for detecting the presence of genetic alterations in the human 5q13 chromosomal region. More specifically, the invention relates to nucleic acids, probes, primers, and methods of using the same, for the amplification and/or the detection of alterations in the human 5q13 chromosomal region, and their correlation to spinal muscular atrophy.Type: GrantFiled: January 29, 1997Date of Patent: March 21, 2000Assignee: Institut National de la Santa et de la Recherche MedicaleInventors: Judith Melki, Arnold Munnich
-
Patent number: 5986051Abstract: This invention relates to Helicobacter polypeptides, particularly UreE, UreF, UreG, UreH, and UreI, immunogenic fragments of those polypeptides, and compositions containing those polypeptides or fragments. This invention also relates to purified antibodies that bind to the polypeptides of this invention and to compositions comprising those antibodies.Type: GrantFiled: July 1, 1994Date of Patent: November 16, 1999Assignees: Institut Pasteur, Institut National de la Santa et de la Recherche MedicaleInventors: Agnes Labigne, Valerie Cussac, Richard Ferrero